Between January and July 2018, Russia imported 291.3 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices), which is in monetary terms 3.2% higher than that of the same period of 2017. The dynamics of the import of in-bulk drugs are +28%, with 62.0 bln RUB. The dynamics of the total pharmaceutical drug import in monetary terms are +7%.

In physical terms, Russia imported around 1 bln units of ready-made drugs, which is 6.5% lower than that of the same period of 2017. If calculated in minimum dosage units (MDU), the dynamics are also negative, -4.1%. As for in-bulk import, the dynamics in MDU are +7%, with 2.6 bln. In total, the dynamics are still negative, -2.9% if calculated in MDU.

In comparison, July had better results. Russia imported 45.9 bln RUB worth of ready-made pharmaceuticals, which is 7.2% higher than that of July 2017. The dynamics of in-bulk import are +79%, with 10.2 bln RUB, which is quite high, although still not record-worthy like in April (11.7 bln RUB.)

Among the top 20 importers, Roche has the biggest dynamics for the period, +97% in monetary terms. The import of its Alecensa has risen by 6.6 times. It is yet to be registered in Russia and has been imported for certain patients for health reasons only. MCD follows with +47%, the import of its Puregon has risen by more than 40 times.

Celgene is the leader among the in-bulk importers, with a 13 times increase. Its most imported product is still Revlimid (import has risen by 84 times.) Amgen follows with a 12 times increase, its most imported product being Nplate, packaged by Dobrolek in Russia.

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2017 – July 2018)